WuXi Bio Reports 24.4 Billion RMB H1 2026 Profit, Up 4.3%; Order Backlog Hits 25.1 Billion USD
WuXi Biologics posted a 4.3% year-on-year rise in shareholder-attributable profit to RMB 2.44 billion for the first half of 2026. Revenue grew 18.43% to RMB 11.787 billion, with adjusted net profit up 38.4% to RMB 3.306 billion. Gross margin widened 3.5 percentage points to 46.2%. The company added 169 integrated projects, bringing the total to 1,064, and its order backlog rose to USD 25.1 billion, including USD 12.6 billion in service orders and USD 12.4 billion in potential milestone payments. No interim dividend was declared.
WuXi Biologics announced its first-half 2026 results, with shareholder-attributable profit reaching RMB 2.44 billion, up 4.3% year on year. Basic earnings per share stood at RMB 0.60, and no interim dividend was declared. Adjusted net profit rose 38.4% to RMB 3.306 billion, while revenue grew 18.43% to RMB 11.787 billion. Gross margin was 46.2%, up 3.5 percentage points from the same period last year. As of end-June, the group added 169 integrated projects, bringing the total to 1,064. Among these, late-stage clinical projects increased to 78 and commercial manufacturing projects to 28. Total order backlog rose to USD 25.1 billion, comprising USD 12.6 billion in outstanding service orders and USD 12.4 billion in potential milestone payments. Meanwhile, the order backlog for the next three years reached USD 5.5 billion as of end-June.